My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts ↗

April 15, 2025

FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility.

Via Benzinga

Topics Economy

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models ↗

April 15, 2025

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.

Via Benzinga

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch ↗

April 15, 2025

Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition.

Via Benzinga

Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved ↗

April 14, 2025

The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.

Via Stocktwits

Topics Economy

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗

April 14, 2025

Pfizer bows, but is not entirely out of the GLP-1 race.

Via The Motley Fool

Recent Filing Shows That Rep. Scott Franklin Bought Over $16K Worth of Novo Nordisk Stock ↗

April 14, 2025

Via Benzinga

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

Is Novo Nordisk Gaining or Losing Market Support? ↗

April 10, 2025

Via Benzinga

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. ↗

April 10, 2025

From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.

Via Investor's Business Daily

Topics Government

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

April 10, 2025

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

Via MarketBeat

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

5 Top Growth Stocks to Buy in the Stock Market Sell-Off ↗

April 09, 2025

Via The Motley Fool

Topics Government

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound ↗

April 08, 2025

CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Via Benzinga

Topics Government

Retail Traders Prefer Novo Nordisk To Eli Lilly After Medicare Shuts Door On Obesity Drug Coverage — But There's More ↗

April 08, 2025

However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population

Via Stocktwits

Topics Government World Trade

Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount ↗

April 07, 2025

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected.

Via Benzinga

Topics World Trade

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): good value for what you're paying. ↗

April 05, 2025

NOVO-NORDISK A/S-SPONS ADR may be an undervalued stock option. NYSE:NVO retains a strong financial foundation and an attractive price tag.

Via Chartmill

Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs ↗

April 04, 2025

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs.

Via Investor's Business Daily

Topics Government

Why Hims & Hers Health Stock Couldn't Beat the Market Today ↗

April 02, 2025

Via The Motley Fool

Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch ↗

April 02, 2025

It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it.

Via Investor's Business Daily

Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales ↗

April 02, 2025

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

Via Benzinga

Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish ↗

April 02, 2025

The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its...

Via Stocktwits

Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now? ↗

April 02, 2025

Via The Motley Fool

Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened? ↗

April 01, 2025

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.

Via Benzinga

Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound ↗

April 01, 2025

The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 01, 2025

Via Benzinga

Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug ↗

March 31, 2025

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%.

Via Benzinga

Which Healthcare Stock Is the Best Buy Right Now?

March 31, 2025

Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.

Via MarketBeat

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst ↗

March 31, 2025

U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.

Via Benzinga

While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60% ↗

March 31, 2025

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting...

Via Benzinga

Topics Economy

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.